Discoveries in Health Policy

Ideas for or from an evolving healthcare system

Tuesday, October 13, 2026

Agilent to acquire Proscia; Business Strategies in Digital Pathology

›
 In headline news today, Agilent (market cap $50B) will acquire Proscia in a deal for $240M in cash.   See news below. I've had a number...

The Strange World of PAMA Neuro Test Pricing

›
Header.    For 24 neuro codes, most were PLA codes with no PAMA data.   For codes with PAMA data (e.g.  5,000 payments for generic ABeta 1-4...
Monday, October 12, 2026

Using Radiology Business "AI" Section to Understand Trends in 2025-2026

›
 I pulled Radiology Business's own listing of 24 recent AI articles - what does it amount to?  Which way and why, are we running? ### Ye...

Rapid Changes Expected for Breast Cancer Therapies; ADCs and More

›
 From Nature Med, Nat Rev Clin Oncol, and NEJM. ## These papers support a substantial opportunity for digital pathology manufacturers—but th...

Katie Palmer's Radiology Articles at STAT: An 8-Article Review and Meta-Analysis

›
We previously used Chat GPT to assess a set of 5 "AI Reimbursement" articles from Katie Palmer at Stat Plus.  Here, we expand the ...

Part 2 of 2: AI Is Amazed by the Novitas-FCSO "MAC LAB DOS" Educational Article

›
In Part 1 , we learned that CMS had asked MACs to  produce a composite standard article that educates on the bizarre Lab Date of Service Rul...

Part 1 of 2: MAC DOS Article: Two AIs Compete to Do Better (Than MACs)

›
Part 1 of 2:  The MAC DOS Article: Two AIs Compete to Do Better (Than MACs) After hearing complaints that the Lab DOS rule should have unifo...

PAMA and Codes for Exome, Genome, and "Rapid Genome"

›
  PAMA 2027: Genome Prices Fall Below Exome—and Rapid Genome Codes Have Missing Data CMS’s preliminary PAMA results point toward a notable r...

Mammography AI Sold Straight to Consumers! (Parallels in Labs?)

›
Everywell will be the agent for seeling Clairity Breast mammography software results to consumers, according to a press release.    In the f...

PAMA and PAP Smears: Strange Goings-On

›
PAMA 2027: When More Cytology Work Brings Less Payment Article by : Chat GPT CMS’s preliminary laboratory pricing data for 2027 offer an une...
Saturday, October 10, 2026

Sepsis: ARPA Grant for Treatable Subtypes; Review

›
ARPA-H Backs a Precision-Immunology Platform for the ICU An award of up to $41.4 million will support a Stanford-led effort to measure chang...
Friday, October 9, 2026

The Stark Law and Pathologist-Owned Labs...and IHC Orders

›
We all know that the Stark law prohibits doctors from referring lab tests to labs they have an ownership in.   How about the daily occurence...

AI Reviews: Three-Day Value Based Cancer Care Conference (VBCC), NYT October 2026

›
  AVBCC 2026 and the work of making cancer care deliver value The 2026 summit of the Association for Value-Based Cancer Care , scheduled for...
›
Home
View web version

About the Author

My photo
Bruce
Bruce Quinn MD PhD is an expert on health reform, innovation, and Medicare policy. He helps both large and small companies understand and overcome hurdles to commercialization, as well as craft business strategies for a changing environment. CONTACT Dr. Quinn through www.brucequinn.com. BACKGROUND: Dr. Quinn has worked in academic medicine, Accenture business strategies, and for the Medicare program. EDUCATION: Stanford MD/PhD, MIT Postdoc, Kellogg MBA.
View my complete profile
Powered by Blogger.